At a glance
ClinicalIndex Comparison RecordN/ACompleted· 54 enrolled
Drug / intervention
Ischemia modified albumin (IMA)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ischemia Modified Albumin as a Biomarker for Prediction of Poor Outcome in Patients With Traumatic Brain Injury. Observational Cohort Study
In Brief
An observational study evaluating Ischemia modified albumin (IMA) for Traumatic Brain Injury. Completed, enrolled 54 participants across 1 site.
Detailed Summary
In the current study the investigators intend to evaluate the role of Ischemia modified albumin (IMA) in the prediction of poor outcome in patients with traumatic brain injury (TBI). The investigators hypothesize that IMA will be elevated in patients with traumatic brain injury due to the excessive production of reactive oxygen species by the injured brain.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTraumatic Brain Injury
CountriesEgypt
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedAug 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedAug 17, 2018
Enrollment StartJun 15, 2018
Primary CompletionDec 7, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.9 years ago
Interventions
Ischemia modified albumin (IMA)other
Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic